DK1682499T3 - 4-biarylyl-1-phenylazetidin-2-oner - Google Patents

4-biarylyl-1-phenylazetidin-2-oner

Info

Publication number
DK1682499T3
DK1682499T3 DK04810780T DK04810780T DK1682499T3 DK 1682499 T3 DK1682499 T3 DK 1682499T3 DK 04810780 T DK04810780 T DK 04810780T DK 04810780 T DK04810780 T DK 04810780T DK 1682499 T3 DK1682499 T3 DK 1682499T3
Authority
DK
Denmark
Prior art keywords
biarylyl
phenylazetidin
img
ones
tif
Prior art date
Application number
DK04810780T
Other languages
English (en)
Inventor
Eduardo Martinez
John J Talley
Stephen Antonelli
Timothy C Barden
Regina Lundrigan-Soucy
Wayne C Schairer
Jing-Jing Yang
Daniel P Zimmer
Brian Cali
Mark G Currie
Peter S Yorgey
Original Assignee
Microbia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbia Inc filed Critical Microbia Inc
Application granted granted Critical
Publication of DK1682499T3 publication Critical patent/DK1682499T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/568—Four-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
DK04810780T 2003-11-10 2004-11-10 4-biarylyl-1-phenylazetidin-2-oner DK1682499T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51869803P 2003-11-10 2003-11-10
US54957704P 2004-03-03 2004-03-03
US59252904P 2004-07-30 2004-07-30
US61400504P 2004-09-28 2004-09-28
PCT/US2004/037715 WO2005047248A1 (en) 2003-11-10 2004-11-10 4-biarylyl-1-phenylazetidin-2-ones

Publications (1)

Publication Number Publication Date
DK1682499T3 true DK1682499T3 (da) 2008-01-02

Family

ID=34596124

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04810780T DK1682499T3 (da) 2003-11-10 2004-11-10 4-biarylyl-1-phenylazetidin-2-oner

Country Status (22)

Country Link
US (2) US7320972B2 (da)
EP (1) EP1682499B1 (da)
JP (1) JP2007520453A (da)
KR (1) KR20070050861A (da)
AT (1) ATE369335T1 (da)
AU (1) AU2004288822A1 (da)
BR (1) BRPI0416361A (da)
CA (1) CA2545058A1 (da)
CY (1) CY1106982T1 (da)
DE (1) DE602004008100T2 (da)
DK (1) DK1682499T3 (da)
EA (1) EA010026B1 (da)
ES (1) ES2291974T3 (da)
HK (1) HK1093974A1 (da)
IL (1) IL175414A0 (da)
MA (1) MA28216A1 (da)
MX (1) MXPA06005106A (da)
NO (1) NO20062665L (da)
NZ (1) NZ546940A (da)
PL (2) PL1682499T3 (da)
PT (1) PT1682499E (da)
WO (1) WO2005047248A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
DK1682499T3 (da) * 2003-11-10 2008-01-02 Microbia Inc 4-biarylyl-1-phenylazetidin-2-oner
BRPI0418004A (pt) 2003-12-23 2007-04-17 Astrazeneca Ab composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, combinação, e, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis
EP1851197A2 (en) * 2005-02-09 2007-11-07 Microbia, Inc. Phenylazetidinone derivatives
US20090186834A1 (en) * 2005-03-24 2009-07-23 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
JP2008539255A (ja) * 2005-04-26 2008-11-13 マイクロビア インコーポレーテッド 高コレステロール血症のための４−ビアリーリル−１−フェニルアゼチジン−２−オングルクロニド誘導体
WO2006121861A2 (en) * 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
TW200726746A (en) 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
AU2006244125A1 (en) * 2005-05-09 2006-11-16 Microbia, Inc. Organometal benzenephosphonate coupling agents
EP1885703A4 (en) * 2005-05-11 2009-09-02 Microbia Inc METHODS FOR PRODUCING 4-BIPHENYLYLAZETIDIN-2-ONE PHENOLIC DERIVATIVES
EP1885694A2 (en) * 2005-05-13 2008-02-13 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
AU2006249905A1 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
CA2611142A1 (en) * 2005-06-15 2006-12-28 Merck & Co., Inc. Anti-hypercholesterolemic compounds
ATE450526T1 (de) 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
WO2008057948A2 (en) * 2006-11-01 2008-05-15 Ironwood Pharmaceuticals, Inc. Processes for production of diphenylylazetidin-2-ones and related compounds
EP2086324A2 (en) * 2006-11-02 2009-08-12 Merck & Co., Inc. Heterocyclyl-substituted anti-hypercholesterolemic compounds
AU2008221833A1 (en) 2007-03-06 2008-09-12 Teijin Pharma Limited 1-biarylazetidinone derivatives
US20080280836A1 (en) * 2007-05-08 2008-11-13 Morriello Gregori J Anti-hypercholesterolemic biaryl azetidinone compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
CA2721060A1 (en) * 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
ES2493916T3 (es) 2009-04-07 2014-09-12 Infinity Pharmaceuticals, Inc. Inhibidores de hidrolasa de amida de ácidos grasos
BR112012003973A2 (pt) 2009-08-26 2015-09-08 Sanofi Sa hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
RU2569061C2 (ru) * 2010-02-03 2015-11-20 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2017066211A1 (en) 2015-10-12 2017-04-20 Advanced Cell Diagnostics, Inc. In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37721A (en) * 1863-02-17 Improvement in hose-couplings
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
EP0596015B1 (en) 1991-07-23 1997-10-01 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5561227A (en) 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
PT1345895E (pt) 2000-12-21 2007-02-28 Sanofi Aventis Deutschland Novas difenilazetidinonas, processo para a sua preparação, fármacos contendo estes compostos e sua utilização para o tratamento de distúrbios do metabolismo lipídico
AU2002240050A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
WO2003026644A1 (en) * 2001-09-21 2003-04-03 Schering Corporation Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2004286838A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents
DK1682499T3 (da) * 2003-11-10 2008-01-02 Microbia Inc 4-biarylyl-1-phenylazetidin-2-oner
EP1885703A4 (en) * 2005-05-11 2009-09-02 Microbia Inc METHODS FOR PRODUCING 4-BIPHENYLYLAZETIDIN-2-ONE PHENOLIC DERIVATIVES
AU2006249905A1 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20080280836A1 (en) * 2007-05-08 2008-11-13 Morriello Gregori J Anti-hypercholesterolemic biaryl azetidinone compounds

Also Published As

Publication number Publication date
EA200600950A1 (ru) 2006-10-27
PL380414A1 (pl) 2007-01-22
DE602004008100T2 (de) 2008-04-30
JP2007520453A (ja) 2007-07-26
ES2291974T3 (es) 2008-03-01
EA010026B1 (ru) 2008-06-30
US7320972B2 (en) 2008-01-22
NO20062665L (no) 2006-08-09
US20050209165A1 (en) 2005-09-22
US20080167255A1 (en) 2008-07-10
CY1106982T1 (el) 2012-09-26
PT1682499E (pt) 2007-11-05
AU2004288822A1 (en) 2005-05-26
KR20070050861A (ko) 2007-05-16
ATE369335T1 (de) 2007-08-15
HK1093974A1 (en) 2007-03-16
EP1682499B1 (en) 2007-08-08
EP1682499A1 (en) 2006-07-26
PL1682499T3 (pl) 2008-01-31
WO2005047248A1 (en) 2005-05-26
BRPI0416361A (pt) 2007-05-08
CA2545058A1 (en) 2005-05-26
IL175414A0 (en) 2006-09-05
DE602004008100D1 (de) 2007-09-20
MA28216A1 (fr) 2006-10-02
NZ546940A (en) 2008-11-28
MXPA06005106A (es) 2007-01-25

Similar Documents

Publication Publication Date Title
CY1106982T1 (el) 4-διαρυλυλο-1-φαινυλαζετιδιν-2-ονες
TW200740752A (en) 4-Biarylyl-1-phenylazetidin-2-ones
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
HUP0402507A2 (hu) N(fenilszulfonil)glicin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
ATE372767T1 (de) Dpp-iv-hemmer
ATE386028T1 (de) Zyklohexylsulfone als gamma-sekretase-inhibitoren
MXPA05012268A (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
ATE368031T1 (de) Neue gamma secretase inhibitoren
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
EA200500862A1 (ru) Синоменин и соединения синоменина, синтез и применение
CY1109300T1 (el) Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
ECSP045214A (es) Proceso para la elaboración de inhibidores de reductasa hmg-coa
EP1997818A3 (en) Quinolinone derivatives and their use to treat pain
ATE380816T1 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
EA200501513A1 (ru) Замещённые 1, 4 - диазепины и их применения
EP2266971A3 (en) Hiv protease inhibiting compounds
DE60202669D1 (de) 6-phenylbenzonaphthyidine
DK1644385T3 (da) Siliciumforbindelser og deres anvendelse
RU2003118102A (ru) 5`-аминокарбонилфосфонаты d4т-ингибиторы репродукции вируса иммунодефицита человека
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf
RU2004102937A (ru) 1-(пиридинил-2)-2-азолил-1-(фторфенил)этанолы и их применение в качестве фунгицидов
RU2003121213A (ru) Гетероциклические о-дикарбонитрилы
PL373989A1 (en) Novel benzonaphthyridines
NO20023040L (no) Triazatrinaftyriner og anvendelsen derav